Advexin: A 2003 phase III clinical trial for Advexin (INGN 101; Ad5CMV-p53) was performed for head and neck cancer, while a 2003 phase II clinical trial was performed for non-small lung cancer [90]. This evidence concerns the gene TP53 and head and neck cancer.